Applying ASCO GU 2024 Data to Clinical Practice in Bladder, RCC Care
Paul V. Viscuse, MD, spotlights key data from the 2024 Genitourinary Cancers Symposium in bladder cancer and renal cell carcinoma.
Source: onclive.com
Robert Motzer News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Robert Motzer. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Robert Motzer Today - Breaking & Trending Today
A Win and A Loss for Adjuvant ICIs in Clear Cell Renal Cell Carcinoma
Pembrolizumab leads to improved OS; single-agent nivolumab fails to impact DFS
Source: medpagetoday.com
Bristol Myers Squibb Data at ASCO GU 2024 Showcase Transformative Research in the Treatment of Genitourinary Cancers
First presentation of results from Phase 3 CheckMate -67T trial with subcutaneous formulation of Opdivo to be shared in a late-breaking oral presentation Four-year data from CheckMate -9ER and...
Source: marketscreener.com
Key Takeaways in the Treatment of Advanced RCC From KCRS 2023
Robert Motzer, MD, and Elizabeth Plimack, MD, discuss clinical findings in the treatment of advanced RCC from the recent KCRS 2023 meeting, emphasizing the significance of circulating tumor cells, advances in imaging, and the potential of adjuvant therapies, particularly pembrolizumab.
Source: onclive.com
Managing Long-Term Toxicities of Combination Lenvatinib and Pembrolizumab in Advanced RCC
Drs Elizabeth Plimack and Robert Motzer discuss the long-term toxicities of combination lenvatinib/pembrolizumab in patients with advanced RCC, highlighting fatigue, GI discomfort, hand-foot syndrome, liver toxicity, thyroid toxicity, and proteinuria.
Source: onclive.com